Update on second primary malignancies in multiple myeloma: A focused review

Leukemia

Volumn 28, Issue 7, 2014, Pages 1423-1426

  Landgren, O ^a   Mailankody, S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

acute myeloid leukemia; lenalidomide; multiple myeloma; myelodysplastic syndromes; secondary malignancy; treatment

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; THALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RISK; CANCER THERAPY; HUMAN; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW; SECOND CANCER;

ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA; NEOPLASMS, SECOND PRIMARY; RISK; THALIDOMIDE;

EID: 84904043247     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.22     Document Type: Review

References (25)

1. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012 366 1759-1769.
2. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012 366 1782-1791.
3. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012 366 1770-1781.
4. Thomas A, Mailankody S, Korde N, Kristinsson SY, Turesson I, Landgren O. Second malignancies after multiple myeloma from 1960s to 2010s. Blood 2012 119 2731-2737.
5. Kyle RA, Pierre RV, Bayrd ED. Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med 1970 283 1121-1125.
6. Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB. The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. New England J Med 1979 301 743-748.
7. Osserman EF, Takatsuki K, Talal N. Multiple myeloma I. the pathogenesis of 'amyloidosis'. Semin Hematol 1964 1 3-85.
8. Mailankody S, Pfeiffer RM, Kristinsson SY, Korde N, Bjorkholm M, Goldin LR et al. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood 2011 118 4086-4092.
9. Roeker LE, Larson DR, Kyle RA, Kumar S, Dispenzieri A, Rajkumar SV. Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS) a population-based study of 17 315 patients. Leukemia 2013 27 1391-1393.
10. Matarraz S, Paiva B, Diez-Campelo M, Corral LL, Perez E, Mateos MV et al. Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma are they present at diagnosis or are they induced by lenalidomide? Haematologica 2012 97 1608-1611.
11. Korde N, Liu QY, Kwok M, Manasanch EE, Simakova O, Mailankody S et al. Early myelodysplastic changes in substantial proportion of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) patients. Blood 2012 120 Abstract 1805.
12. Waldenstroem J. Melphalan therapy in myelomatosis. Br Med J 1964 1 859-865.
13. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983 2 822-824.
14. Usmani SZ, Sexton R, Hoering A, Heuck CJ, Nair B, Waheed S et al. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma influence of thalidomide and lenalidomide during maintenance. Blood 2012 120 1597-1600.
15. Dimopoulos MA, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012 119 2764-2767.
16. Srivastava G, Rana V, Lacy MQ, Buadi FK, Hayman SR, Dispenzieri A et al. Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. Leukemia 2013 27 2062-2066.
17. Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani SZ, Waage A et al. Second primary malignancies with lenalidomide therapy for newly diagnosed multiple myeloma a meta-analysis of individual patient data. Lancet Oncol 2014 15 333-342.
18. Kantarjian HM, Keating MJ, Walters RS, Smith TL, Cork A, McCredie KB et al. Therapy-related leukemia and myelodysplastic syndrome clinical, cytogenetic and prognostic features. J Clin Oncol 1986 4 1748-1757.
19. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011 118 4771-4779.
20. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012 26 2326-2335.
21. Dualan R, Brody T, Keeney S, Nichols AF, Admon A, Linn S. chromosomal localization and cDNA cloning of the genes (DDB1 and DDB2) for the p127 and p48 subunits of a human damage-specific DNA binding protein. Genomics 1995 29 62-69.
22. Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of improved survival in patients with multiple myeloma in the twenty-first century a population-based study. J Clin Oncol 2010 28 830-834.
23. Kristinsson SY, Anderson WF, Landgren O. Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia 2014 28 1341.
24. Usmani SZ, Crowley J, Hoering A, Mitchell A, Waheed S, Nair B et al. Improvement in long-term outcomes with successive total therapy trials for multiple myeloma are patients now being cured? Leukemia 2013 27 226-232.
25. Landgren O, Thomas A, Mailankody S. Myeloma and second primary cancers. N Engl J Med 2011 365 2241-2242.